Ethical, scientific issues related to 'post-market' clinical trials

Amid growing concerns about clinical trials for drugs that have been approved by the FDA but are later linked to serious health risks, an independent committee at the Institute of Medicine has developed a conceptual framework to guide the agency through the tough decision of ordering such controversial "post-market" drug-safety trials.

Read the whole article on Science Daily

More from Science Daily